SkylineDx’s Merlin Test Recognized by NCCN for Melanoma
By Karen Roman SkylineDx said its Merlin CP-GEP molecular test is uniquely recognized by the National Comprehensive Cancer Network (NCCN) for predictive use in select T1 and T2 melanoma patients. The test provides informed risk stratification and helps physicians better understand...